Danaher's New CEO Rewrites the Report Card — but Keeps the Old Guidance

A fresh chief executive, a 29% ninety-day rally, and a 2027 framework that stops exactly where the old one did

DHR · Earnings Call · 2026-10-21

The tape voted before the transcript arrived

Danaher walked into this print up 29.1% over ninety trading days — a one-segment, straight-up move — and still sits 20.6% below its September 2021 peak of $294.67. That combination is the whole setup: a violently re-rated stock attached to a business that has spent three years explaining why growth is slower than it used to be. The multiple compression explains the rally's fuel. Price to operating income is 26.1x, down 18% year over year and 38% below the 41.9x peak set in 2024Q3; price to revenue sits at 5.3x versus 8.5x back then. Investors were not paying for the past. They were paying for a new CEO. Julie Sawyer Montgomery, nine years at Danaher, three weeks into the job, delivered her first call. The quarter itself was good: sales of $6.6 billion, core growth of 5.5% excluding respiratory (a ~250 basis point respiratory headwind dragged reported core to 3%), adjusted operating margin of 29% up 110 basis points, adjusted EPS of $2.11 up about 11.5%, and full-year EPS guidance raised to $8.57–$8.62 from $8.45–$8.60. What matters more is the language change.

A new vocabulary, and an old one retired

For six quarters this company's calls were organized around end-market recovery: activity level, policy headwinds, funnel activity, equipment order, easy comps. The current call is organized around selling. The two highest-conviction phrases are commercial execution and unambiguous share gain, the latter framed as the company's actual scorecard rather than a slogan.

When I talk to our teams, I say that unambiguous share gain is our true report card. I want to preserve what makes us great, but also ensure we are focused on the most important priorities for who we are today.
Julie Sawyer Montgomery, President and Chief Executive Officer · 2026-10-21

The mechanism she describes is a more connected Danaher — showing up across operating companies to lift share of wallet, a push she says has already generated "several hundred millions of dollars of opportunity in a short time" in Diagnostics. Note that commercial execution was already a Danaher keyword a quarter ago, but buried near the bottom of the stack; this quarter it is the CEO's headline. That is a promotion, not an invention — and worth flagging, since she is careful to say the operating-company structure stays.

Two quiet subtractions that matter more than the additions

What management stopped emphasizing is more revealing than what it added. First, respiratory. The endemic rate assumption has been walked down in stages: in October 2025 it was "similar to 2025 at sort of that endemic rate we've talked about of $1.7 billion"; by April 2026 the framing had drifted to getting "back to that kind of endemic $1.8 billion rate." On this call it became: “We are planning for $1.5 billion in respiratory this year, and I think that's also the right starting point for next year as well.” — Julie Sawyer Montgomery, President and Chief Executive Officer · 2026-10-21 That is a $200–300 million reset in the base, dressed as prudence about a middling flu season. It is defensible — the ILI curve hasn't crossed 3% — but it is also a smaller Diagnostics business embedded in the starting point for 2027, and it quietly lowers the bar everyone will measure the new CEO against. Second, China volume-based procurement. Across prior calls this was a quantified, repeated headwind — $150 million in 2025, $75–100 million planned for 2026. Today it is a passing phrase: China "up high single digits" with "easing China policy related headwinds." The headwind has not so much been solved as aged out. Investors should treat its disappearance as a comp effect, not a new growth engine.

The tension: mid-teens orders, a mid-single-digit frame

Here is where the call gets genuinely interesting. Bioprocessing orders grew mid-teens, with equipment orders in strong double digits and backlog building. Any normal reading of that order book says 2027 accelerates. Instead, Matt Gugino framed next year as flat to history:

As we look to 2027, we think that 4%-5% core revenue growth, excluding respiratory revenue, is the right starting point as we sit today.
Matt Gugino, Executive Vice President and Chief Financial Officer · 2026-10-21

Tycho Peterson said the quiet part: with resin delays rolling off, China VBP lapsing, biotech funding converting and academics improving, "why on earth would ex-respiratory be the same?" The answer was process — the Q4 planning cycle, a January update. Fair, but this is the same company that said in April, "It's April of 2026, I think we're a little bit too early to talk about '27," and in January that there was "no change whatsoever to what we have been talking about for a while now" on bioprocessing as a high-single-digit grower. The high single digit claim is now a five-quarter refrain; repetition is not evidence. The reshoring optionality got the same treatment — finally sized ("it could be a billion-dollar market opportunity in the U.S.") and immediately deferred ("more of a 2028 plus event"). Note the keyword: reshoring and equipment order chatter dominated late-2025 calls and has slipped out of the top of this company's keyword stack entirely, consistent with a theme that is real but not yet orderable.

The AI story the tape is not currently paying for

Danaher's AI pitch is not the one being sold off. The AI data center basket is down 5.6% over ninety days with 48 decliners to 6 advancers in the market's own tape — capex skepticism, not enthusiasm. Danaher's version is the autonomous lab at Abcam: AI designs the experiment, Danaher instruments and reagents run it, results feed the next loop, claimed 8x faster reagent discovery and 10x throughput, plus a NVIDIA collaboration and work with Anthropic on instrument-agent standards. It is the most company-unique idea on the call. Julie was also honest that it is "not material today" — a scientific discovery narrative attached to a P&L that won't see it for years. What the P&L does show is cash. Free cash flow less stock comp of $1.17 billion against net income of $870 million gives a conversion of roughly 1.35x — the quality-of-earnings argument that has always underwritten this franchise. Revenue of $6.27 billion grew 6% with gross margin holding near 58%. The offset is the balance sheet. Effective net cash of -$22.2 billion reflects Masimo and StatLab, and $894 million of buyback in the latest reported quarter was executed while leverage rose. Management's stated bias stays compounding M&A, which is the right bias — but the room for error is thinner than it was in 2024.

What to watch

Nothing in this quarter falsifies the re-rating; nothing yet confirms it either. The concrete tests arrive fast: Q4 core growth ex-respiratory guided to 4–5% (a deceleration from 5.5%), a 29.5% adjusted margin, and then January's formal 2027 number. If bioprocessing orders keep compounding mid-teens and the framework still lands at 4–5%, the market will conclude the ceiling is structural, not cyclical — and a 26x operating-income multiple for mid-single-digit growth will feel expensive again. If instead the January guide creeps above 5% with respiratory reset to $1.5 billion, the report card starts to read the way the new CEO wants it to.